Development and Validation of Stability-Indicating HPLC Methods for Quantitative Determination of Pravastatin,Fluvastatin, Atorvastatin,and Rosuvastatin in Pharmaceuticals

Abstract

High-performance liquid-chromatographic (HPLC) methods were validated for determination of pravastatin sodium (PS), fluvastatin sodium (FVS), atorvastatin calcium (ATC), and rosuvastatin calcium (RC) in pharmaceuticals. Two stability-indicating HPLC methods were developed with a small change (10%) in the composition of the organic modifier in the mobile phase. The HPLC method for each statin was validated using isocratic elution. An RP-18 column was used with mobile phases consisting of methanol–water (60:40, v/v, for PS and RC and 70:30, v/v, for FVS and ATC). The pH of each mobile phase was adjusted to 3.0 with orthophosphoric acid, and the flow rate was 1.0 mL/min. Calibration plots showed correlation coefficients (r) > 0.999, which were calculated by the least square method. The detection limit (DL) and quantitation limit (QL) were 1.22 and 3.08 µg/mL for PS, 2.02 and 6.12 µg/mL for FVS, 0.44 and 1.34 µg/mL for ATC, and 1.55 and 4.70 µg/mL for RC. Intraday and interday relative standard deviations (RSDs) were <2.0%. The methods were applied successfully for quantitative determination of statins in pharmaceuticals.     

Utility of Certain π‐Acceptors for the Spectrophotometric Determination of Tranexamic Acid in Commercial Dosage Forms

Abstract

In this study, two simple, fast, accurate, and sensitive spectrophotometric methods have been developed for the determination of tranexamic acid in commercial dosage forms. These methods (A and B) are based on the reaction of tranexamic acid as n‐electron donor with 2,3‐dichloro‐5,6‐dicyano‐1,4‐benzoquinone (DDQ) and 7,7,8,8‐tetracyanoquinodimethane (TCNQ) as π‐acceptors to give highly colored complex species that absorb maximally at 470 and 750 nm, respectively. Beer's law was obeyed in the concentration limit of 0.5–10 µg/mL for tranexamic acid. The limit of detection (LOD) and limit of quantification (LOQ) were calculated and found to be 0.18 µg/mL and 0.60 µg/mL for method A and 0.12 µg/mL and 0.39 µg/mL for method B, respectively. A Job's plot of the absorbance versus the molar ratio of tranexamic acid to each of the acceptors under consideration indicated 1∶1. The proposed methods were found to be rapid, accurate, precise, and sensitive for the determination of tranexamic acid in commercial dosage forms without interferences from common additives encountered.     

Simultaneous Determination of Levomepromazine Hydrochloride and Its Sulfoxide by UV‐Derivative Spectrophotometry and Bivariate Calibration Method

Abstract

Two spectrophotometric methods are proposed for the simultaneous quantification of levomepromazine hydrochloride (LV) and its main degradation product levomepromazine sulfoxide (LV‐SO). One of them is based on the first order derivative spectra generated by the Savitzky‐Golay algorithm (third‐order polynomial degree, Δλ=10 nm). Determination of levomepromazine hydrochloride and its sulfoxide was realized by measurements of amplitudes of derivative spectra at 332 nm and 278 nm, respectively. The Beer law was obeyed in the concentration range 1.5–50 µg/mL for LV and 2.5–50 µg/mL for LV‐SO. The second of the proposed methods utilized the bivariate calibration algorithm. The determination was performed at 302 nm for levomepromazine and at 334 nm for sulfoxide. The elaborated methods allowed determination of LV in the concentration range 1.0–25 µg/mL while LV‐SO was determined in the concentration range 2.0–50 µg/mL.     

Liquid Chromatographic Determination of Glyoxal and Methylglyoxal from Serum of Diabetic Patients using Meso‐Stilbenediamine as Derivatizing Reagent

Abstract

Meso‐stilbenediamine has been used as derivatizing reagent for liquid chromatographic (LC) determination of glyoxal (Go), methylglyoxal (MGo), and dimethylglyoxal (DMGo) at pH 3. Liquid chromatographic elution and separation was carried out from the column Kromasil 100 C‐18, 5 µm (15×0.46 mm i.d.) with methanol: water:acetonitrile (59:40:1, v/v/v) with a flow rate of 1 mL/min and ultraviolet detection at 254 nm. The linear calibration curves were obtained for Go, MGo, and DMGo within 0.97–4.86 µg/mL, 1.52–7.6 µg/mL, and 1.41–7.08 µg/mL with detection limits of 48 ng/mL, 76 ng/mL, and 70.8 ng/mL, respectively. The method was applied for the determination of Go and MGo from serum of patients suffering from diabetes and ketosis. The amounts of Go and MGo found were 0.150–0.260 µg/mL and 0.160–0.270 µg/mL with coefficient of variation (C.V.) 2.6–4.7% and 2.5–4.6%, respectively. The results obtained were compared with normal subjects with Go and MGo contents of 0.025–0.065 µg/mL and 0.030–0.070 µg/mL with C.V 1.5–4.9% and 1.6–4.8% in the serum.     

Development of an Ion-Pair HPLC Method for Determination of Acebutolol in Pharmaceuticals

A simple and accurate ion-pair reversed-phase high-performance liquid chromatographic (RP-HPLC) method has been developed and validated for determination of acebutolol (ACE) in tablet dosage forms. Both ACE and ambroxol (internal standard) were well separated using a reversed phase column and a mobile phase consisting of a mixture of methanol-0.05 M acetic acid (containing 8 mM sodium 1-heptanesulfanate) (65:35 v/v) with pH adjusted to 3.2 with triethylamine. The mobile phase was pumped at 0.80 mL min^?1 flow rate and ACE was detected by diode-array detection at 240 nm. The retention times for ACE and internal standard (IS) were 4.574 and 8.236 min, respectively. A linear response (r = 0.9998) was observed in the range of 0.27–2.93 μg mL^?1 in mobile phase. The limit of detection and limit of quantification were found as 0.07 and 0.23 μg mL^?1 in the mobile phase. Validation parameters such as precision, accuracy, selectivity, reproducibility, and system suitability tests were also determined. The excipients did not interfere with the assay of ACE in tablet dosage forms. It is suggested that the proposed method can be used for routine quality control and dosage-form assay of ACE.     

Development and validation of a simple and isocratic reversed‐phase HPLC method for the determination of rilpivirine from tablets,nanoparticles and HeLa cell lysates

In the present investigation, a simple and isocratic HPLC‐UV method was developed and validated for determination of rilpivirine (RPV) from dosage forms (tablets and nanoparticles) and biological matrices like HeLa cell lysates. The separation and analysis of RPV was carried out under isocratic conditions using (a) a Gemini reversed‐phase C₁₈ column (5 µm; 4.6 × 150 mm) maintained at 35°C, (b) a mobile phase consisting of a mixture of acetonitrile and 25 m m potassium dihydrogen phosphate (in the ratio 50:50 v/v) at a flow rate of 0.6 mL/min and (c) atazanavir as an internal standard. The total run time was 17 min and the analysis of RPV and internal standard was carried out at 290 nm. The method was found to be linear (r² value > 0.998), specific, accurate and precise over the concentration range of 0.025–2 µg/mL. The lower limit of quantification was 0.025 µg/mL, the limit of detection was 0.008 µg/mL and the recovery of RPV was >90%. The stability of the RPV analytical method was confirmed at various conditions such as room temperature (24 h), ?20°C (7 days), three freeze?thaw cycles and storage in an autosampler (4°C for 48 h). The method was successfully applied for the determination of RPV from conventional dosage forms like tablets, from polymeric nanoparticles and from biological matrices like HeLa cell lysates. Copyright © 2014 John Wiley & Sons, Ltd.     

Electrochemical Determination of Sulphur‐containing Pharmaceuticals Using Boron‐doped Diamond Electrodes

N‐acetylcysteine (NAC) and gentamicin sulfate (GS) are biologically and pharmaceutically relevant thiol‐containing compounds. NAC is well known for its antioxidant properties, whereas GS is an aminoglycoside that is used as a broadband antibiotic. Both pharmaceuticals play a significant role in the treatment of bacterial infections by suppressing the formation of biofilms. According to the European Pharmacopeia protocol, GS is analyzed by high performance liquid chromatography (HPLC) using gold electrodes for electrochemical detection. Here, we report the electrochemical detection of these compounds at NH₂‐terminated boron‐doped diamond electrodes, which show significantly reduced electrode passivation, an issue commonly known for gold electrodes. Cyclic voltammetry experiments performed for a period of 70 minutes showed that the peak current decreased only by 1.6 %/7.4 % for the two peak currents recorded for GS, and 6.6 % for the oxidation peak of NAC, whereas at gold electrodes a decrease in peak current of 14.2 % was observed for GS, and of 64 %/30 % for the two peak currents of NAC. For their quantitative determination, differential pulse voltammetry was performed in a concentration range of 2–49 µg/mL of NAC with a limit of detection (LOD) of 1.527 µg/mL, and a limit of quantification (LOQ) of 3.624 µg/mL, respectively. The quantification of GS in a concentration range of 0.2–50 µg/mL resulted in a LOD of 1.714 µg/mL, and a LOQ of 6.420 µg/mL, respectively.     

Applying green analytical chemistry for development and validation of RP-HPLC stability indicating assay method for estimation of fenoverine in bulk and dosage form using quality by design approach

A green and robust reverse-phase liquid chromatographic method has been developed for the determination of fenoverine (FEN), by applying combined principles of green analytical chemistry and quality by design approaches on a Spherisorb C18 column (150?×?4.6?mm, 3?µm) with UV detection at 262?nm. A two level fractional factorial design (2^^7-3) Res IV was used for screening of influential chromatographic factors. The critical method parameters actively affecting critical quality attributes (CQAs) were identified and further optimized using Box–Behnken design. The predicted optimum assay conditions comprised of methanol and ammonium acetate buffer 20?mM, in an extent of 81:19% v/v individually having a flow rate of 1.0?mL/min with a column oven temperature of 33°C. The drug was stressed in hydrolytic, oxidative, reductive, thermal, and photolytic conditions. The developed method was validated successfully. The detector response was linear in the concentration of 0.5–160?µg/mL with a limit of detection (LOD) and limit of quantitation (LOQ) as 0.1 and 0.3?µg/mL, respectively. The % recovery was found to be 99.7%. The analytical method volume intensity value for developed method was 45?mL and the environment assessment tool (EAT) score was 41.07. The method is simple, environmentally benign, rapid, and robust for the determination of FEN in bulk and in its dosage form.     

Liquid Chromatographic Analysis of Cephalexin in Human Plasma by Fluorescence Detection of the 9-Fluorenylmethyl Chloroformate Derivative

Abstract

A simple and sensitive precolumn derivatization method for the determination of cephalexin in human plasma has been developed. Cephalexin was derived with 9-fluorenylmethyl chloroformate (FMOC-Cl) in borate buffer (5 mM, pH 8.5) for 15 min at 25°C. Optimal conditions for the derivatization were described. The derivative was chromatographed on an XDB-C₁₈ column with water–acetonitrile (10:90, v/v) as mobile phase at a flow rate of 1.0 mL/min. The fluorescence excitation and emission wavelengths were 268 nm and 314 nm, respectively. The standard curve in spiked plasma was linear over the range of 0.0234–58.5 µg/mL; the detection limit (signal-to-noise ratio = 3; injection volume, 10 µL) was about 0.014 µg/mL. The performance of analysis was studied, and the validated method showed excellent performance in terms of selectivity, sensitivity, precision, and accuracy.     

Ion-Pair RP-LC of Tegaserod Maleate and its Impurities in Pharmaceutical Formulations and in Dissolution Studies

A simple ion-pair reversed-phase high-performance liquid chromatographic (RP-HPLC) method has been developed for determination of tegaserod maleate and related impurities in tablet dosage forms. The mobile phase was 60:40 (v/v) acetonitrile-25 mmol L^?1 sodium dodecyl sulfate, adjusted to pH 2.6 with glacial acetic acid. A C18 column was used as stationary phase and UV detection was at 314 nm. The method was optimized and validated. Response was linearly dependent on concentration between 0.1 and 100 µg mL^?1 with a limit of quantification (LOQ) of 0.1 µg mL^?1 for tegaserod maleate (S/N = 10). Under optimum conditions, tegaserod maleate was successfully separated from related substances, including 5-methoxyindole-3-carboxaldehyde remaining after synthesis and other impurities possibly resulting from oxidization and decomposition. The excipients did not interfere with assay of tegaserod maleate in tablet dosage forms. It is suggested that the proposed method can be used for routine quality control and dosage-form assay of tegaserod maleate.     

A fast and green reversed‐phase HPLC method with fluorescence detection for simultaneous determination of amlodipine and celecoxib in their newly approved fixed‐dose combination tablets

A fast, green, sensitive, and accurate analytical method using high‐performance liquid chromatography couple with fluorescence detection was established and validated for the simultaneous determination of amlodipine besylate and celecoxib in their recently approved fixed‐dose combination tablets (1:20). Separation of the two drugs was achieved on C₁₈ reversed‐phase column (Thermo ODS Hypersil, 4.6 × 250 mm, particle size 5 µm) using acetonitrile:potassium phosphate buffer (50 mM; pH 5.5, 60:40 v/v) as a mobile phase at 40°C, which eluted at a rate of 1 mL/min. Detection was carried out with excitation and emission wavelengths of 360 and 446 nm for amlodipine and 265 and 359 nm for celecoxib, respectively. The method was linear over a concentration range of 0.05‐2 and 0.05‐10 µg/mL and limit of detection reached to 0.017 and 0.0167 µg/mL for amlodipine and celecoxib, respectively. The developed method was successfully applied to assess the cited drugs in their newly FDA approved fixed‐dose combination tablet dosage form. Furthermore, the method was found to be sensitive and eco‐friendly green alternative to the reported methods as it was evaluated according to the green analytical procedure index tool guidelines and analytical Eco‐Scale.     

Estimation of Alprazolam and Sertraline in Pure Powder and Tablet Formulations by High-Performance Liquid Chromatography and High-Performance Thin-Layer Chromatography

Abstract

This article describes validated high-performance liquid chromatographic (HPLC) and high-performance thin-layer chromatographic (HPTLC) methods for simultaneous estimation of alprazolam (ALZ) and sertraline (SER) in pure powder and tablet formulation. The HPLC separation was achieved on a Nucleosil C18 column (150 mm long, 4.6 mm i.d., and 5-µm particle size) using acetonitrile and phosphate buffer (50 + 50 v/v), pH 5.5, as the mobile phase at a flow rate of 1.0 mL/min at ambient temperature. The HPTLC separation was achieved on an aluminum-backed layer of silica gel 60 F₂₅₄ using acetone/toluene/ammonia (6.0:3.0:1.0, v/v/v) as the mobile phase. Quantification with the HPLC method was achieved with ultraviolet (UV) detection at 230 nm over the concentration range 3–18 µg/mL for both drugs with mean recovery of 101.86 ± 0.21 and 100.57 ± 0.31% for ALZ and SER, respectively. Quantification in HPTLC was achieved with UV detection at 230 nm over the concentration range of 400–1400 ng/spot for both drugs with mean recoveries of 101.32 ± 0.15 and 100.38 ± 0.51% for ALZ and SER, respectively. These methods are rapid, simple, precise, sensitive, and are applicable for the simultaneous determination of ALZ and SER in pure powder and formulations.     

Stability-indicating method for the determination of assay and quantification of impurities in amlodipine–atorvastatin combination dosage form by RP-HPLC

A simple stability-indicating RP-HPLC method was developed and validated for quantification of amlodipine, atorvastatin, and its impurities on Waters HPLC using Unisol C₁₈ 5?µm, 250?×?4.6?mm column in their combined tablet dosage as per ICH guidelines. The gradient (T/%B) at 0/42, 18/42, 22/75, 30/75, 32/42, and 35/42 of 40?mM 4.7 pH ammonium acetate as mobile phase A and acetonitrile as mobile phase B of flow rate 1.5?mL/min and 240?nm wavelength. Peak purity compiled for amlodipine and atorvastatin in all stressed conditions. For impurities: Precision was found in between 1.5 and 3.6%. The limit of detection and quantification for amlodipine, amlodipine impurity A, and atorvastatin was found to be 0.06 and 0.18?µg/mL, for atorvastatin Impurity A, B, C, and H was determined as 0.04 and 0.11?µg/mL, for Atorvastatin Impurity D was measured as 0.11 and 0.28?µg/mL, respectively. The linear regression achieved >0.9999 from 0.22 to 7.5?µg/mL. Recovery was observed in between 97 and 101%. For assay: Precision was determined in between 0.1 and 0.2%. The linear regression achieved >0.9999 for amlodipine and atorvastatin. Recovery ranged from 100 to 101%. The validated method was found to be accurate, precise, reliable, and robust to determine the assay as well as impurities in amlodipine–atorvastatin combination dosage formulation.     

Simultaneous Determination of Cephradine,L‐Arginine,and Cephalexin in Cephradine for Injection by Capillary Zone Electrophoresis

Abstract

Applying capillary zone electrophoresis (CZE) to separate the components of Cephradine for Injection: cephradine, and L‐arginine, as well as cephalexin, which is the degradation product of cephradine was studied. The best results were achieved with background electrolyte consisting of 50 mM disodium hydrogen phosphate buffer at pH 6.5 and an applied voltage of 20 kV in a bare fused‐silica capillary. The samples were injected at 50 mbar for 4 s. The capillary temperature was 25°C and the UV detection was performed at a wavelength of 195 nm. Histidine was used as internal standard (IS) to ensure acceptable precision data. The linear ranges of cephradine, L‐arginine, and cephalexin were 93.8–6255.6 µg/mL, 47.9–3195.2 µg/mL, and 6.1–405.4 µg/mL, respectively. Quantitative parameters such as accuracy, precision, limit of detection (LOD), and limit of quantitation(LOQ) were all established in CZE mode.     

Multivariate optimization of a capillary zone electrophoresis assay method for simultaneous quantification of metformin and vildagliptin from a formulation

A rapid, accurate, precise, and optimized capillary zone electrophoresis assay was established and validated for the simultaneous quantification of metformin and vildagliptin in tablets. The electrophoretic separation was achieved on an untreated bonded silica capillary with a background electrolyte comprising 25 mM of borate buffer at pH 7.5 at 207 nm. The concentration of the buffer and the pH of BGE were optimized using the multivariate optimization method for determining the retention time and peak area. Furthermore, the sample injection time, capillary oven temperature, and applied voltage were optimized. The capillary zone electrophoresis technique was validated for all required parameters as per the International Conference on Harmonization recommendations. The linearity ranged in the concentrations of 5–500 µg/mL and 5–100 µg/mL with the limit of detections of 0.22 µg/mL and 0.40 µg/mL for metformin and vildagliptin, respectively. In addition, the percent relative standard error for repeatability and inter-day precision was within the acceptable range. The mean recoveries determined by the capillary zone electrophoresis method were 99.2% and 100.4% for metformin and vildagliptin, respectively. Finally, the capillary zone electrophoresis process was effectively used for the assays of metformin and vildagliptin in their solid dosage form, and statistical outcomes were in agreement with the outcomes of the previously validated RP-HPLC method.     

Development and Validation of RP-HPLC Method for Simultaneous Estimation of Three-Component Tablet Formulation Containing Acetaminophen,Chlorzoxazone, and Aceclofenac

Abstract

The present work describes a simple reversed-phase high-performance liquid chromatographic method that has been developed and validated for simultaneous estimation of acetaminophen, chlorzoxazone, and aceclofenac in tablet dosage form. The estimation was carried out on an Luna C₁₈ (5 µm × 25 cm × 4.6 mm i.d.) column using a mixture of buffer, methanol, and acetonitrile in the ratio 215:130:155 with final pH of 6.5 as a mobile phase, at a flow rate of 1.5 ml/min. Ultraviolet (UV) detection was performed at 275 nm. Total run time was 10 min; these three drugs (acetaminophen, chlorzoxazone, and aceclofenac) were eluted at the retention times of 2.055, 5.096, and 7.605 min respectively. The method was validated for accuracy, precision, linearity, specificity, and sensitivity as per ICH norms.. From the validation study it was found that the method is specific, rapid, accurate, precise, and reproducible. Calibration curves were linear over the concentration ranges of 5–50 µg/ml for acetaminophen and chlorzoxazone, and 5–30 µg/ml for aceclofenac. All the validation study was found statistically significant because all the statistical parameters were within the acceptance range (i.e., COV % < 2.0 and S.D. < 1.0 for both accuracy and precision). The limit of detection (LOD) values were 16.2, 14.6, and 4.8 ng/ml, and LOQ values were 49.0, 46.5, and 14.5 ng/ml for acetaminophen, chlorzoxazone, and aceclofenac respectively. High recovery and low COV % revealed the reliability of the method for quantitative study of three drugs in Micronac-MR tablets. The method is a rapid and cost-effective quality-control tool for routine quantitative analysis of acetaminophen, chlorzoxazone, and aceclofenac in tablet dosage form.     

Simple and Sensitive High-Performance Liquid Chromatographic Method for Determination of Transdermally Applied Flurbiprofen in Rat Plasma and Excised Skin Samples

A simple reversed-phase HPLC method has been developed for determination of flurbiprofen in rat plasma, excised skin extract, and transdermal patch formulations. The mobile phase was methanol–1% (v/v) phosphoric acid in water, 80:20 (v/v), at a flow rate of 0.5 mL min^-1; ibuprofen was used as internal standard. Flurbiprofen and ibuprofen was detected by UV absorption at 254 nm and 220 nm, respectively. The limit of quantitation was 0.1 µg mL^-1. The response was linearly dependent on concentration in the range 0.1–10 µg mL^-1, and accuracy and reproducibility were good. At these concentrations intraday and interday assay variability were below 8%. Recovery of flurbiprofen was greater than 94% over the linear range of calibration plot.     

Determination of Nimesulide by Ion Pair High-Performance Liquid Chromatography Using Tetrabutylammonium as the Counterion

A new method for nimesulide was developed using ion-pair reversed phase liquid chromatography and tetrabutylammonium hydrogen sulfate as the ion-pairing reagent. The influence of the ion pair forming reagent concentration, pH, and mobile phase composition on the retention time of nimesulide were studied. The optimum experimental conditions included a C18 column, a mobile phase of a 50/50 (v/v) mixture of acetonitrile and 15 mM phosphate buffer (pH 8.00) containing 6 mM tetrabutylammonium hydrogen sulfate, 25°C, isocratic elution, a flow rate of 1 mL/min, a run time of 10 minutes, and photodiode array detection at 404 nm. From the analysis of the results, the mechanism for the separation of nimesulide was also established. The retention time for nimesulide was 4.76 ± 0.05 min. The method was linear between concentrations of 9 µg/mL to 64 µg/mL, with limits of detection and quantification of 1.111 µg/mL and 3.390 µg/mL, respectively. The method is simple, rapid, accurate, and precise, and successfully applied for the determination of nimesulide in pharmaceutical products.     

Flow Injection Post-Chemiluminescence Reaction of Astemizole in N-Bromosuccinimide-Calcein System and Its Application

A flow injection post chemiluminescence (FI-PCL) reaction was found when astemizole was mixed with the CL reaction mixture of N-bromosuccinimide and calcein under alkaline conditions. Based on this observation, a simple and sensitive post chemiluminescence (PCL) technique for the assay of astemizole was described. Under the optimized conditions, the PCL values responded linearly to the concentration of astemizole in the range 1.0 × 10^?3–3.0 µg/mL, with a detection limit of 7.0 × 10^?4 µg/mL. The relative standard deviation was 1.7% for 1.0 × 10^?2 µg/mL astemizole solution (n = 13). It was applied to the determination of astemizole in pharmaceutical preparations with satisfactory results.     

HPLC estimation of iothalamate to measure glomerular filtration rate in humans

Glomerular filtration rate (GFR) is usually determined by estimation of iothalamate (IOT) clearance. We have developed and validated an accurate and robust method for the analysis of IOT in human plasma and urine. The mobile phase consisted of methanol and 50 mM sodium phosphate (10:90; v/v). Flow rate was 1.2 mL/min on a C18 reverse phase column, Synergi-hydro (250 × 4.6 mm) 4 µm 80 Å, with an ultraviolet detector set to 254 nm. Acetonitrile was used for the deproteination and extraction of IOT from human plasma and urine. Precision and accuracy were within 15% for IOT in both plasma and urine. The recoveries of IOT in urine and plasma ranged between 93.14% and 114.74 and 96.04–118.38%, respectively. The linear range for urine and plasma assays were 25–1500 and 1–150 µg/mL respectively. The lower limits of detection were 0.5 µg/mL for both urine and plasma, with no interference from plasma and urine matices. This method has been fully validated according to FDA guidelines and the new HPLC assay has been applied to a new formulation of IOT (Conray? 43), to calculate GFR in healthy volunteers. The new method is simple, less expensive and it would be instrumental in future clinical and pharmacokinetic studies of iothalamate in kidney patients.